Here's what's interesting. When EXAS first started developing this test several years ago, they reported specificity of 85% and many "experts" whispered behind the sciences that while 85% a good result, the specificity would slip in the final trial putting the number below acceptable. 87% specificity is looking pretty good relative to those first numbers.
EXAS ($9.10) continues in modest recovery mode and is now down only 11% from the pre-release share price at Wednesday’s close. The enterprise value is now in the vicinity of $500M.
Market Data 
Markets 
AI
